Literature DB >> 3004243

Pulmonary scar cancer. A pathologic reappraisal.

I T Kung, I O Lui, S L Loke, M A Khin, C K Mok, W K Lam, S Y So.   

Abstract

A total of 49 consecutive specimens of lung cancer were collected prospectively at surgical resection or autopsy from 40 men and nine women, aged 40-74 years. Of the 49 tumors, the gross appearance of 22 fitted the description of a scar cancer, i.e., a tumor with pleural puckering and central pigmentation. Nineteen of the "scar cancers" were peripheral (17 adenocarcinomas and two squamous cell carcinomas); three were central (one squamous cell carcinoma and two adenocarcinomas). In the 19 peripheral "scar cancers," elastic stains demonstrated the presence of collapsed, unfibrosed lung tissue at the center with traction of the overlying pleura toward it. Elsewhere in the tumor, the elastic framework was either destroyed or expanded by tumor filling the alveolar spaces. None of the "scar cancers" had a significant desmoplastic reaction that might otherwise explain the scarred appearance. It appeared that local atelectasis was solely responsible for the pleural puckering and central pigmentation. On the other hand, atelectatic lung tissue was not seen in the 27 cancers that did not have the appearance of a scar cancer. Tuberculosis was found in 10 of the 49 lung specimens. In only one specimen was the tuberculous lesion anatomically associated with the tumor. There was no evidence of pulmonary infarct in any of the specimens. The term "scar cancer" was considered inappropriate as there was no preformed fibrous tissue. The scarred appearance was thought to be the result of localized pulmonary atelectasis owing to small airways obstruction by tumor. Association with tuberculosis was considered incidental.

Entities:  

Mesh:

Year:  1985        PMID: 3004243     DOI: 10.1097/00000478-198506000-00001

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  9 in total

1.  Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia.

Authors:  F Kumaki; K Matsui; T Kawai; Y Ozeki; Z X Yu; V J Ferrans; W D Travis
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

2.  Alveolar atypical hyperplasia in association with primary pulmonary adenocarcinoma: a clinicopathological study of 10 cases.

Authors:  F A Carey; W A Wallace; R J Fergusson; K M Kerr; D Lamb
Journal:  Thorax       Date:  1992-12       Impact factor: 9.139

3.  Scar adenocarcinoma of the lung.

Authors:  I Kung
Journal:  J Clin Pathol       Date:  1987-02       Impact factor: 3.411

4.  Incidence of atypical bronchioloalveolar cell hyperplasia of the lung: relation to histological subtypes of lung cancer.

Authors:  S Y Weng; E Tsuchiya; T Kasuga; H Sugano
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

5.  Chronic rhinosinusitis and risk of lung cancer in the Singapore Chinese Health Study.

Authors:  Woon-Puay Koh; Jian-Min Yuan; Renwei Wang; Adeline Seow; Hin-Peng Lee; Mimi C Yu
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

6.  Mesothelioma-like tumors of the pleura: a review of 72 autopsy cases.

Authors:  C A Hartmann; H Schütze
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 7.  Bacterial infection as a cause of cancer.

Authors:  J Parsonnet
Journal:  Environ Health Perspect       Date:  1995-11       Impact factor: 9.031

Review 8.  Early glandular neoplasia of the lung.

Authors:  W H Westra
Journal:  Respir Res       Date:  2000-11-17

Review 9.  Elastin in pulmonary pathology: relevance in tumours with a lepidic or papillary appearance. A comprehensive understanding from a morphological viewpoint.

Authors:  Erik Thunnissen; Noriko Motoi; Yuko Minami; Daisuke Matsubara; Wim Timens; Yukio Nakatani; Yuichi Ishikawa; Ximena Baez-Navarro; Teodora Radonic; Hans Blaauwgeers; Alain C Borczuk; Masayuki Noguchi
Journal:  Histopathology       Date:  2021-09-23       Impact factor: 7.778

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.